Purchase suggestions:

The company is a RNA therapy biopharmaceutical company with candidate products in the preclinical and clinical stages, focusing on the exploration and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics was founded in 2007 and currently occupies a market position in China and the United States, with R & D centers in both countries. The company's core product, STP705, has proven efficacy and safety in oncology phase I/II clinical trials of non-melanoma skin cancer, further advancing STP705 phase clinical trials of squamous cell carcinoma in situ (isSCC) for phase IIb, phase II clinical trials for the treatment of basal cell carcinoma of the skin (BCC), phase II clinical trials for keloid and phase I/II clinical trials for hypertrophic scars (HTS). In addition, according to the independent IND approval of FDA in the United States, the company has launched a phase I clinical trial of local injection of STP705 in the treatment of liver cancer (basket). At present, two authorized patents and seven pending patent applications in the United States cover our core product STP705, including two in China and five in the United States.

STP705, a dual and TGF- β 1 / COX-2 inhibitor, successfully completed a phase I/II clinical trial for the treatment of NMSC (especially isSCC) in the United States in October 20, and launched a phase IIb clinical trial of isSCC in the United States in May 21. Interim results are expected in the first half of 22 years. Supplementation to IND involving isSCC also launched a phase II clinical trial of non-melanoma basal cell carcinoma (BCC) in the United States in December 20. NMSC, including squamous cell carcinoma (SCC) and BCC, is the most common form of tumor in the United States. The conventional and standard treatments for BCC and isSCC are standard surgical resection, Morse microsurgery, topical ointment, cryotherapy, laser therapy, electrodrying and radiotherapy. Currently, the United States FDA has approved two drugs for pre-metastatic BCC patients, both of which are used outside the label of pre-metastatic SCC patients: 5-fluorouracil and imiquimod topical ointment. According to the cautery counseling report, both of them can cause skin reactions in some patients.